NCT06997029 2026-03-16
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Recruiting
Clinical Trials
22 trialsNCT03006172 2026-03-11
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Genentech, Inc.
Phase 1 Active not recruiting
NCT04288089 2026-02-27
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer
Eisai Inc.
Phase 1 Active not recruiting
NCT03332797 2026-02-13
A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
Genentech, Inc.
Phase 1 Active not recruiting
NCT02499146 2026-02-11
Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer
Pfizer
Phase 1 Completed
NCT05238922 2026-02-10
Study of INCB123667 in Subjects With Advanced Solid Tumors
Incyte Corporation
Phase 1 Recruiting
NCT05266105 2025-11-24
A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients
Olema Pharmaceuticals, Inc.
Phase 1 Active not recruiting
NCT04185883 2025-10-22
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
Phase 1 Active not recruiting
NCT04606446 2025-08-13
KAT6
Pfizer
Phase 1 Recruiting
NCT06570031 2025-07-02
ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer
Ono Pharmaceutical Co. Ltd
Phase 1 Active not recruiting
NCT06941142 2025-04-23
A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1 Not yet recruiting
NCT05384119 2025-02-21
Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
Tvardi Therapeutics, Incorporated
Phase 1 Terminated
NCT05178888 2025-02-11
Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)
Mirati Therapeutics Inc.
Phase 1 Completed
NCT05293964 2024-11-29
Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Active not recruiting
NCT04060862 2024-11-08
IPATunity150
Hoffmann-La Roche
Phase 1 Terminated
NCT02599714 2024-06-06
PASTOR
AstraZeneca
Phase 1 Completed
NCT03455270 2022-12-15
G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer
G1 Therapeutics, Inc.
Phase 1 Completed
NCT02684032 2022-07-27
A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer
Celcuity Inc
Phase 1 Completed
NCT04856371 2021-04-23
Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer
Haihe Biopharma Co., Ltd.
Phase 1 Unknown
NCT02065063 2018-06-01
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00420056 2015-10-28
An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.
Pfizer
Phase 1 Completed
NCT01602887 2012-11-12
Relative Bioavailability Study
Pfizer
Phase 1 Completed